Vanguard Capital Management
BBIO icon

Vanguard Capital Management’s BridgeBio Pharma BBIO Stock Holding History

Vanguard Capital Management’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$588M Buy
7,898,973
+139,478
+2% +$9.77M 0.01% 646
2026
Q1 		$576M Buy
+7,759,495
New +$562M 0.01% 617

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Vanguard Capital Management's BBIO Position: Q2 2026 in Review

Vanguard Capital Management increased its BridgeBio Pharma (BBIO) stake by 1.8% in Q2 2026, buying an estimated $9.77M and bringing the position to 7,898,973 shares worth $588M. The position accounts for 0.01% of the portfolio, ranked #646.

Vanguard Capital Management first reported a position in BBIO in Q1 2026 and has held it in 2 quarters since. 439 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Vanguard Capital Management held 7,898,973 shares of BridgeBio Pharma worth $588M as of Q2 2026.
  • Vanguard Capital Management bought 139,478 BridgeBio Pharma shares in Q2 2026, an estimated $9.77M.
  • BridgeBio Pharma made up 0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #646 holding.
  • Vanguard Capital Management first reported a position in BridgeBio Pharma in Q1 2026 and has held it in 2 quarters since.
  • 439 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.